Most cancer drugs are designed to interfere with one or more events in cell proliferation or
survival. As healthy cells may also need to proliferate and avoid apoptosis, anticancer …

Here, we review potential determinants of the anticancer efficacy of innate immune peptides
(ACPs) for cancer cells. These determinants include membrane‐based factors, such as …

In this text, the small team of expert authors presents the field in a comprehensive and
accessible manner that is well suited for students and junior researchers. The result is a …

Targeted therapies are designed to interfere with specific aberrant biologic pathways
involved in tumor development. The main classes of novel oncologic drugs include …

Angiogenesis is a hallmark for cancer development because it is essential for cancer growth
and provides the route for cancer cell migration (metastasis). Understanding the mechanism …

Cancer is one of the most frequent and distressing diseases. The mortality caused by cancer
and its prevalence has increased during the last 50 years. Cancer is still one of the most …

Advances in genomics have enabled anticancer therapies to be tailored to target specific
genomic alterations. Single-arm trials (SATs), including those incorporated within umbrella …

Various cancer treatment approaches have shown promising results when tested
preclinically. The results of clinical trials, however, are often disappointing. While searching …

Phorbol ester (TPA) treatment of human U937 myeloid leukemia cells is associated with
increasing adherence and monocyte-like maturation whereby the role of β 2 integrin …

Combination therapy with 2 or more drugs with different mechanisms of action has been
considered a promising strategy for the effective treatment of advanced and metastatic …